Immune MMF S 360 Tablet DR contains Mycophenolate sodium 360 mg, an immunosuppressive agent primarily indicated for the prevention of organ transplant rejection. Mycophenolate sodium acts by selectively inhibiting inosine monophosphate dehydrogenase, a key enzyme in the de novo synthesis of guanine nucleotides, thereby suppressing the proliferation of T and B lymphocytes which are critical in the immune response. The delayed-release (DR) formulation enhances gastrointestinal tolerability by minimizing direct gastric irritation and improving drug absorption in the small intestine. Immune MMF S 360 is commonly prescribed as part of a combination immunosuppressive regimen, including corticosteroids and calcineurin inhibitors, to reduce the risk of acute and chronic rejection in renal, cardiac, or hepatic transplant recipients. The drug requires careful dose adjustment and monitoring due to potential adverse effects such as gastrointestinal disturbances, hematologic abnormalities (e.g., leukopenia, anemia), and increased susceptibility to infections. Patients should be regularly monitored for signs of infection, blood cell counts, and renal function. Mycophenolate sodium is contraindicated in pregnancy due to teratogenic risk and should be used with caution in patients with active infections or hematologic disorders. Proper adherence to prescribed dosing and medical supervision is essential to optimize therapeutic outcomes and minimize complications.